Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CENTURY THERAPEUTICS, INC.

(IPSC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Century Therapeutics : Piper Sandler Starts Century Therapeutics at Overweight With $38 Price Target

07/13/2021 | 06:06am EDT


ę MT Newswires 2021
All news about CENTURY THERAPEUTICS, INC.
10/13CENTURY THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/07CENTURY THERAPEUTICS : Outpace Bio Enter Cell Therapy Research Collaboration
MT
10/07CENTURY THERAPEUTICS : and Outpace Bio Enter Research Collaboration in CAR Engineering
AQ
10/07Century Therapeutics and Outpace Bio Enter Research Collaboration in Car Engineering
CI
09/20CENTURY THERAPEUTICS, INC.(NASDAQGS : IPSC) added to S&P TMI Index
CI
09/17CENTURY THERAPEUTICS : Announces Its Addition to the Russell 2000« Index
AQ
08/12CENTURY THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Business Updates ..
PU
08/12CENTURY THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD ..
AQ
08/12CENTURY THERAPEUTICS : Earnings Flash (IPSC) CENTURY THERAPEUTICS Reports Q2 Loss $-1.93
MT
08/12CENTURY THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Business Updates
AQ
More news
Analyst Recommendations on CENTURY THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -84,6 M - -
Net cash 2021 348 M - -
P/E ratio 2021 -9,15x
Yield 2021 -
Capitalization 1 159 M 1 159 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 121
Free-Float 88,8%
Chart CENTURY THERAPEUTICS, INC.
Duration : Period :
Century Therapeutics, Inc. Technical Analysis Chart | IPSC | US15673T1007 | MarketScreener
Technical analysis trends CENTURY THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 21,31 $
Average target price 36,25 $
Spread / Average Target 70,1%
EPS Revisions
Managers and Directors
Osvaldo Flores Chief Executive Officer & Director
Douglas Carr Vice President-Finance & Operations
Joseph Jimenez Chairman
Hyam I. Levitsky President-Research & Development
Cynthia M. Butitta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CENTURY THERAPEUTICS, INC.0.00%1 159
MODERNA, INC.234.60%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.58%49 076
SEAGEN INC.0.22%31 189
CELLTRION, INC.-39.69%25 455